Abstract | PURPOSE OF REVIEW: RECENT FINDINGS: SUMMARY: Unmet need for efficacious therapy in IIMs exists and therefore a coordinated effort is necessary to properly evaluate various new classical and biological agents.
|
Authors | Heřman F Mann, Jiří Vencovský |
Journal | Current opinion in rheumatology
(Curr Opin Rheumatol)
Vol. 23
Issue 6
Pg. 605-11
(Nov 2011)
ISSN: 1531-6963 [Electronic] United States |
PMID | 21926626
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Antibodies, Monoclonal, Humanized
- Antibodies, Monoclonal, Murine-Derived
- Antibodies, Neoplasm
- Glucocorticoids
- Immunoglobulins, Intravenous
- Immunosuppressive Agents
- Interleukin 1 Receptor Antagonist Protein
- Tumor Necrosis Factor-alpha
- Alemtuzumab
- Rituximab
- tocilizumab
|
Topics |
- Alemtuzumab
- Antibodies, Monoclonal, Humanized
(therapeutic use)
- Antibodies, Monoclonal, Murine-Derived
(therapeutic use)
- Antibodies, Neoplasm
(therapeutic use)
- Clinical Trials as Topic
- Dermatomyositis
(therapy)
- Glucocorticoids
(therapeutic use)
- Humans
- Immunoglobulins, Intravenous
(therapeutic use)
- Immunosuppressive Agents
(therapeutic use)
- Interleukin 1 Receptor Antagonist Protein
(therapeutic use)
- Mesenchymal Stem Cell Transplantation
- Myositis
(therapy)
- Rituximab
- Tumor Necrosis Factor-alpha
(antagonists & inhibitors)
|